WASHINGTON, D.C. — Oscar‑nominee Barry Keoghan appeared in a social‑media video posted by UK‑based facial expert Nilam Holmes, showcasing his recent Xerf skin‑tightening session, a radio‑frequency treatment that claims to stimulate collagen without injections.

The clip, released on TikTok on September 12, shows Keoghan reclined in Dermaspa’s London clinic while a technician operates the Xerf device. The treatment, priced at £2,495 (≈ $3,200), is marketed as a non‑surgical alternative to facelifts, promising visible tightening within two weeks and a full course of three sessions over six months.

Dermaspa, founded by Holmes in 2018, reports a 42 % year‑over‑year increase in bookings for non‑invasive procedures, driven in part by celebrity endorsements. “When high‑profile clients like Barry share their experience, it validates the technology for a broader audience,” Holmes said in a statement to the press.

Industry analysts note that the global market for radio‑frequency cosmetic devices is projected to reach $5.1 billion by 2028, up from $3.4 billion in 2023, according to a report by Grand View Research. Investors are watching the sector closely as regulatory frameworks in the EU and US tighten around medical‑grade aesthetic equipment.

Regulators in the United Kingdom have classified Xerf as a Class II medical device, requiring compliance with the Medical Devices Regulation (MDR) and mandatory post‑market surveillance. The European Commission’s recent guidance on “non‑invasive aesthetic procedures” could affect pricing, reimbursement, and cross‑border service provision.

Key Takeaways

• Barry Keoghan’s participation highlights growing consumer interest in non‑surgical cosmetic solutions.
• Dermaspa’s revenue surge mirrors a broader 42 % increase in demand for radio‑frequency treatments worldwide.
• Regulatory scrutiny in the EU and US may shape future investment strategies for firms offering similar technologies.

As the aesthetic industry expands, stakeholders—from venture capital firms to policy makers—will need to balance market growth with patient safety standards, ensuring that high‑profile endorsements do not outpace evidence‑based practice.